For research use only. Not for therapeutic Use.
Apricitabine（Cat No.:M032709）is a nucleoside reverse transcriptase inhibitor (NRTI) developed for the treatment of HIV infection. It targets the reverse transcriptase enzyme, essential for HIV replication, by incorporating itself into the viral DNA and causing premature chain termination. Apricitabine has shown efficacy against strains of HIV that are resistant to other NRTIs, making it a promising option for patients with drug-resistant HIV. Its favorable safety profile and low incidence of side effects enhance its potential as part of combination antiretroviral therapies, providing an alternative treatment option for managing HIV/AIDS.
| Catalog Number | M032709 |
| CAS Number | 160707-69-7 |
| Molecular Formula | C8H11N3O3S |
| Purity | ≥95% |
| Target | Anti-infection |
| Storage | Store at -20°C |
| IUPAC Name | 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one |
| InChI | InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m1/s1 |
| InChIKey | RYMCFYKJDVMSIR-RNFRBKRXSA-N |
| SMILES | C1C(SC(O1)CO)N2C=CC(=NC2=O)N |
| Reference | </br>1:Renal excretion of apricitabine in rats: ex vivo and in vivo studies. Babayeva M, Cox S, White MP, Taft DR.Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):141-50. doi: 10.1007/s13318-011-0038-9. Epub 2011 Apr 6. PMID: 21744041 </br>2:Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy. Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper DA, Cox S.HIV Med. 2011 Jul;12(6):334-42. doi: 10.1111/j.1468-1293.2010.00887.x. Epub 2010 Nov 3. PMID: 21054750 Free Article</br>3:Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. Cahn P, Wainberg MA.J Antimicrob Chemother. 2010 Feb;65(2):213-7. doi: 10.1093/jac/dkp422. Epub 2009 Dec 9. Review. PMID: 20007333 </br>4:Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study. Cox S, Southby J, Linet O, Tackwell K, Borin M, Perry K.Clin Drug Investig. 2009;29(11):721-8. doi: 10.2165/11319890-000000000-00000. PMID: 19813775 </br>5:Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection. Gaffney MM, Belliveau PP, Spooner LM.Ann Pharmacother. 2009 Oct;43(10):1676-83. doi: 10.1345/aph.1M160. Epub 2009 Sep 8. Review. PMID: 19737995 </br>6:Apricitabine–a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Cox S, Southby J.Expert Opin Investig Drugs. 2009 Feb;18(2):199-209. doi: 10.1517/13543780802641337 . Review. PMID: 19236266 </br>7:Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations. Oliveira M, Moisi D, Spira B, Cox S, Brenner BG, Wainberg MA.Antimicrob Agents Chemother. 2009 Apr;53(4):1683-5. doi: 10.1128/AAC.01168-08. Epub 2009 Feb 17. PMID: 19223637 Free PMC Article</br>8:Apricitabine continues to show good results. Dalton P.Proj Inf Perspect. 2008 Sep;(46):12. No abstract available. PMID: 19043879 </br>9:Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor. Holdich T, Sawyer J.Expert Opin Pharmacother. 2008 Aug;9(12):2021-5. doi: 10.1517/14656566.9.12.2021 . PMID: 18671458 </br>10:Pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers treated with trimethoprim-sulphamethoxazole. Shiveley L, Struthers-Semple C, Cox S, Sawyer J.J Clin Pharm Ther. 2008 Feb;33(1):45-54. doi: 10.1111/j.1365-2710.2008.00889.x. PMID: 18211616 |
